English

RAPT Therapeutics, Inc.

EDGAR

RAPT Current report (8-K) · filed 2026-03-03

40 filing records in this dataset, filed from 2016-05-05 to 2026-03-03. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2023 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-27.8 million USD

2023 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -97048000 USD Source
Operating Cash Flow: -69294000 USD Source

Free cash flow

-27.8 million USD

2023 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -97048000 USD Source
Operating Cash Flow: -69294000 USD Source
Capital Expenditure: 1125000 USD Source
Capital Expenditure: 1058000 USD Source

Cash and cash equivalents: 37.9 million USD 2025-09-30 Source
Exact value

37930000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 132 million shares 2024-12-31 Source
Exact value

132006828 shares

Reported share-count change

283.76% · 97.6 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

34398312 shares · 2023-12-31· Source
132006828 shares · 2024-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-106 million USD

2024-10-01 – 2025-09-30

Exact inputs and evidence

Net income: -129865000 USD · 2024-01-01 – 2024-12-31 Source
Net income: -76616000 USD · 2024-01-01 – 2024-09-30 Source
Net income: -17165000 USD · 2025-01-01 – 2025-03-31 Source
Net income: -17643000 USD · 2025-04-01 – 2025-06-30 Source
Net income: -17580000 USD · 2025-07-01 – 2025-09-30 Source

Operating cash flow

-86.6 million USD

2024-10-01 – 2025-09-30

Exact inputs and evidence

Operating cash flow: -83300000 USD · 2024-01-01 – 2024-12-31 Source
Operating cash flow: -72860000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -52414000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -63685000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -52414000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -76143000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -63685000 USD · 2025-01-01 – 2025-06-30 Source

Capital expenditure

84 thousand USD

2024-10-01 – 2025-09-30

Exact inputs and evidence

Capital expenditure: 122000 USD · 2024-01-01 – 2024-12-31 Source
Capital expenditure: 121000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 43000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 83000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 43000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 83000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 83000 USD · 2025-01-01 – 2025-06-30 Source

Free cash flow

-86.7 million USD

2024-10-01 – 2025-09-30

Exact inputs and evidence

Operating cash flow: -83300000 USD · 2024-01-01 – 2024-12-31 Source
Operating cash flow: -72860000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -52414000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -63685000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -52414000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -76143000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -63685000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 122000 USD · 2024-01-01 – 2024-12-31 Source
Capital expenditure: 121000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 43000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 83000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 43000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 83000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 83000 USD · 2025-01-01 – 2025-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-03-03.

Financial data available through: 2023-12-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2023-12-31
Operating income: 7 of 11 periods available· newest 2023-12-31
Net income: 7 of 11 periods available· newest 2023-12-31
Operating cash flow: 7 of 11 periods available· newest 2023-12-31
Capital expenditure: 7 of 11 periods available· newest 2023-12-31
Total assets: 4 of 11 periods available· newest 2023-12-31
Total liabilities: 4 of 11 periods available· newest 2023-12-31
Current assets: 4 of 11 periods available· newest 2023-12-31
Current liabilities: 4 of 11 periods available· newest 2023-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2023-12-31
long term debt: No compatible figures in this window
Shares outstanding: 4 of 11 periods available· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-100%

Prior period

USD 1.53 million

2022-01-01 – 2022-12-31
Current period

USD 0

2023-01-01 – 2023-12-31

Exact inputs and evidence

0 − 1527000 = -1527000 USD

1527000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
0 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · RAPT Therapeutics, Inc. · 2023-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Year-over-year change in Revenue: -1527000 USD Concept: fundies:Revenue Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017024027594/rapt-20231231.htm#1254870 Filing: 000095017024027594 Input fundies:Revenue: 1527000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017024027594/rapt-20231231.htm#1256091 Filing: 000095017024027594
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 32.96 million

Prior period

−USD 83.84 million

2022-01-01 – 2022-12-31
Current period

−USD 116.8 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-116798000 − -83838000 = -32960000 USD

-83838000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-116798000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · RAPT Therapeutics, Inc. · 2023-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Year-over-year change in Net income: -32960000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -116798000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017025034185/rapt-20241231.htm#2336259 Filing: 000095017025034185 Input fundies:NetIncome: -83838000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017024027594/rapt-20231231.htm#2166146 Filing: 000095017024027594
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 26.28 million

Prior period

−USD 70.77 million

2022-01-01 – 2022-12-31
Current period

−USD 97.05 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-97048000 − -70771000 = -26277000 USD

-70771000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-97048000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · RAPT Therapeutics, Inc. · 2023-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Year-over-year change in Operating cash flow: -26277000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -97048000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017025034185/rapt-20241231.htm#1523083 Filing: 000095017025034185 Input fundies:OperatingCashFlow: -70771000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017024027594/rapt-20231231.htm#1474963 Filing: 000095017024027594
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+33.1%

Prior period

USD 845,000

2022-01-01 – 2022-12-31
Current period

USD 1.13 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

1125000 − 845000 = 280000 USD

845000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
1125000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · RAPT Therapeutics, Inc. · 2023-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Year-over-year change in Capital expenditure: 280000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1125000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017025034185/rapt-20241231.htm#1536568 Filing: 000095017025034185 Input fundies:CapitalExpenditure: 845000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017024027594/rapt-20231231.htm#1485790 Filing: 000095017024027594
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 0
Operating costs Derived USD 127.06 million
Operating income −USD 127.06 million
Tax, interest and other Derived −USD 10.26 million
Net income −USD 116.8 million

Cash

Operating cash flow −USD 97.05 million
Capital expenditure USD 1.13 million
Free cash flow Derived −USD 98.17 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 1,155% of revenue.
2021 Operating loss: operating costs were 1,915% of revenue.
2022 Operating loss: operating costs were 5,719% of revenue.
2023 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	5042000	58256000 Derived	-53214000	-322000 Derived	-52892000	-40889000 Derived	Source 2020-01-01 – 2020-12-31: 5042000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -53214000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -52892000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -40491000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 398000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	3813000	73022000 Derived	-69209000	-5000 Derived	-69204000	-61781000 Derived	Source 2021-01-01 – 2021-12-31: 3813000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -69209000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -69204000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -61026000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 755000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	1527000	87322000 Derived	-85795000	-1957000 Derived	-83838000	-71616000 Derived	Source 2022-01-01 – 2022-12-31: 1527000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -85795000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -83838000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -70771000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 845000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	0	127062000 Derived	-127062000	-10264000 Derived	-116798000	-98173000 Derived	Source 2023-01-01 – 2023-12-31: 0 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -127062000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -116798000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -97048000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 1125000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	5042000	Revenue: 5042000 Open source
20212021-12-31	Revenue	3813000	Revenue: 3813000 Open source
20222022-12-31	Revenue	1527000	Revenue: 1527000 Open source
20232023-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 5042000 Open source
20212021-12-31	Year over year	-24.4%	Revenue: 3813000 Open source Revenue: 5042000 Open source
20222022-12-31	Year over year	-60%	Revenue: 1527000 Open source Revenue: 3813000 Open source
20232023-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 1527000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -5,618.5% 2022

Net margin -5,490.4% 2022

Free cash flow margin -4,690% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-1,055.4%	Operating Income: -53214000 Open source Revenue: 5042000 Open source
20212021-12-31	Operating margin	-1,815.1%	Operating Income: -69209000 Open source Revenue: 3813000 Open source
20222022-12-31	Operating margin	-5,618.5%	Operating Income: -85795000 Open source Revenue: 1527000 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -127062000 Open source Revenue: 0 Open source
20202020-12-31	Net margin	-1,049%	Net Income: -52892000 Open source Revenue: 5042000 Open source
20212021-12-31	Net margin	-1,814.9%	Net Income: -69204000 Open source Revenue: 3813000 Open source
20222022-12-31	Net margin	-5,490.4%	Net Income: -83838000 Open source Revenue: 1527000 Open source
20232023-12-31	Net margin	Not reported	Net Income: -116798000 Open source Revenue: 0 Open source
20202020-12-31	Free cash flow margin	-811%	Revenue: 5042000 Open source Operating Cash Flow: -40491000 Open source Capital Expenditure: 398000 Open source
20212021-12-31	Free cash flow margin	-1,620.3%	Revenue: 3813000 Open source Operating Cash Flow: -61026000 Open source Capital Expenditure: 755000 Open source
20222022-12-31	Free cash flow margin	-4,690%	Revenue: 1527000 Open source Operating Cash Flow: -70771000 Open source Capital Expenditure: 845000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -97048000 Open source Capital Expenditure: 1125000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -97M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-40491000	Operating Cash Flow: -40491000 Open source
20212021-12-31	Operating cash flow	-61026000	Operating Cash Flow: -61026000 Open source
20222022-12-31	Operating cash flow	-70771000	Operating Cash Flow: -70771000 Open source
20232023-12-31	Operating cash flow	-97048000	Operating Cash Flow: -97048000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -98.2M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-40889000	Operating Cash Flow: -40491000 Open source Capital Expenditure: 398000 Open source
20212021-12-31	Free cash flow	-61781000	Operating Cash Flow: -61026000 Open source Capital Expenditure: 755000 Open source
20222022-12-31	Free cash flow	-71616000	Operating Cash Flow: -70771000 Open source Capital Expenditure: 845000 Open source
20232023-12-31	Free cash flow	-98173000	Operating Cash Flow: -97048000 Open source Capital Expenditure: 1125000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

15.2% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	12.4%	Total Liabilities: 14790000 Open source Total Assets: 118969000 Open source
20212021-12-31	Liabilities / assets	6.2%	Total Liabilities: 12256000 Open source Total Assets: 198636000 Open source
20222022-12-31	Liabilities / assets	7.9%	Total Liabilities: 21043000 Open source Total Assets: 266209000 Open source
20232023-12-31	Liabilities / assets	15.2%	Total Liabilities: 26294000 Open source Total Assets: 173329000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

7.41× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	9.84×	Current Assets: 115598000 Open source Current Liabilities: 11742000 Open source
20212021-12-31	Current assets / current liabilities	20.11×	Current Assets: 192973000 Open source Current Liabilities: 9595000 Open source
20222022-12-31	Current assets / current liabilities	17.77×	Current Assets: 252694000 Open source Current Liabilities: 14224000 Open source
20232023-12-31	Current assets / current liabilities	7.41×	Current Assets: 161782000 Open source Current Liabilities: 21836000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2017-01-01 – 2017-12-31	−USD 29.12 million Exact value Exact value: -29115000 USD 2017-01-01 – 2017-12-31: -29115000 USD Inspect Net Income Open source Share or cite Citation for Net Income · RAPT Therapeutics, Inc. · 2017-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Net Income: -29115000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29115000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000119312520024342/rapt-20190930.xml#456544 Filing: 000119312520024342 The citation records this snapshot. The page link may show a newer release later.	−USD 27.12 million Exact value Exact value: -27123000 USD 2017-01-01 – 2017-12-31: -27123000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · RAPT Therapeutics, Inc. · 2017-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Operating Cash Flow: -27123000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -27123000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000119312520024342/rapt-20190930.xml#462894 Filing: 000119312520024342 The citation records this snapshot. The page link may show a newer release later.	USD 1.12 million Exact value Exact value: 1124000 USD 2017-01-01 – 2017-12-31: 1124000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · RAPT Therapeutics, Inc. · 2017-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Capital Expenditure: 1124000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1124000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000119312520024342/rapt-20190930.xml#461101 Filing: 000119312520024342 The citation records this snapshot. The page link may show a newer release later.	−USD 28.25 million Calculation and evidence -27123000 − 1124000 USD Exact free cash flow: -28247000 USD 2017-01-01 – 2017-12-31: -27123000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 1124000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · RAPT Therapeutics, Inc. · 2017-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Free cash flow: -28247000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -27123000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000119312520024342/rapt-20190930.xml#462894 Filing: 000119312520024342 Input fundies:CapitalExpenditure: 1124000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000119312520024342/rapt-20190930.xml#461101 Filing: 000119312520024342 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 36.15 million Exact value Exact value: -36147000 USD 2018-01-01 – 2018-12-31: -36147000 USD Inspect Net Income Open source Share or cite Citation for Net Income · RAPT Therapeutics, Inc. · 2018-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Net Income: -36147000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -36147000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000156459020014162/rapt-20191231.xml#108121 Filing: 000156459020014162 The citation records this snapshot. The page link may show a newer release later.	−USD 32.95 million Exact value Exact value: -32953000 USD 2018-01-01 – 2018-12-31: -32953000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · RAPT Therapeutics, Inc. · 2018-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Operating Cash Flow: -32953000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -32953000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000156459020014162/rapt-20191231.xml#131427 Filing: 000156459020014162 The citation records this snapshot. The page link may show a newer release later.	USD 3.5 million Exact value Exact value: 3500000 USD 2018-01-01 – 2018-12-31: 3500000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · RAPT Therapeutics, Inc. · 2018-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Capital Expenditure: 3500000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3500000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000156459020014162/rapt-20191231.xml#132264 Filing: 000156459020014162 The citation records this snapshot. The page link may show a newer release later.	−USD 36.45 million Calculation and evidence -32953000 − 3500000 USD Exact free cash flow: -36453000 USD 2018-01-01 – 2018-12-31: -32953000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 3500000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · RAPT Therapeutics, Inc. · 2018-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Free cash flow: -36453000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -32953000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000156459020014162/rapt-20191231.xml#131427 Filing: 000156459020014162 Input fundies:CapitalExpenditure: 3500000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000156459020014162/rapt-20191231.xml#132264 Filing: 000156459020014162 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 43 million Exact value Exact value: -42997000 USD 2019-01-01 – 2019-12-31: -42997000 USD Inspect Net Income Open source Share or cite Citation for Net Income · RAPT Therapeutics, Inc. · 2019-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Net Income: -42997000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -42997000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000156459021012250/rapt-20201231.xml#116840 Filing: 000156459021012250 The citation records this snapshot. The page link may show a newer release later.	−USD 35.47 million Exact value Exact value: -35474000 USD 2019-01-01 – 2019-12-31: -35474000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · RAPT Therapeutics, Inc. · 2019-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Operating Cash Flow: -35474000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35474000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000156459021012250/rapt-20201231.xml#139857 Filing: 000156459021012250 The citation records this snapshot. The page link may show a newer release later.	USD 888,000 Exact value Exact value: 888000 USD 2019-01-01 – 2019-12-31: 888000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · RAPT Therapeutics, Inc. · 2019-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Capital Expenditure: 888000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 888000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000156459021012250/rapt-20201231.xml#141533 Filing: 000156459021012250 The citation records this snapshot. The page link may show a newer release later.	−USD 36.36 million Calculation and evidence -35474000 − 888000 USD Exact free cash flow: -36362000 USD 2019-01-01 – 2019-12-31: -35474000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 888000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · RAPT Therapeutics, Inc. · 2019-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Free cash flow: -36362000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35474000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000156459021012250/rapt-20201231.xml#139857 Filing: 000156459021012250 Input fundies:CapitalExpenditure: 888000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000156459021012250/rapt-20201231.xml#141533 Filing: 000156459021012250 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 52.89 million Exact value Exact value: -52892000 USD 2020-01-01 – 2020-12-31: -52892000 USD Inspect Net Income Open source Share or cite Citation for Net Income · RAPT Therapeutics, Inc. · 2020-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Net Income: -52892000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -52892000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000156459022009488/rapt-10k_20211231.htm#2479036 Filing: 000156459022009488 The citation records this snapshot. The page link may show a newer release later.	−USD 40.49 million Exact value Exact value: -40491000 USD 2020-01-01 – 2020-12-31: -40491000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · RAPT Therapeutics, Inc. · 2020-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Operating Cash Flow: -40491000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -40491000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000156459022009488/rapt-10k_20211231.htm#1716410 Filing: 000156459022009488 The citation records this snapshot. The page link may show a newer release later.	USD 398,000 Exact value Exact value: 398000 USD 2020-01-01 – 2020-12-31: 398000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · RAPT Therapeutics, Inc. · 2020-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Capital Expenditure: 398000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 398000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000156459022009488/rapt-10k_20211231.htm#1735999 Filing: 000156459022009488 The citation records this snapshot. The page link may show a newer release later.	−USD 40.89 million Calculation and evidence -40491000 − 398000 USD Exact free cash flow: -40889000 USD 2020-01-01 – 2020-12-31: -40491000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 398000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · RAPT Therapeutics, Inc. · 2020-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Free cash flow: -40889000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -40491000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000156459022009488/rapt-10k_20211231.htm#1716410 Filing: 000156459022009488 Input fundies:CapitalExpenditure: 398000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000156459022009488/rapt-10k_20211231.htm#1735999 Filing: 000156459022009488 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 69.2 million Exact value Exact value: -69204000 USD 2021-01-01 – 2021-12-31: -69204000 USD Inspect Net Income Open source Share or cite Citation for Net Income · RAPT Therapeutics, Inc. · 2021-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Net Income: -69204000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -69204000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017023007710/rapt-20221231.htm#2954282 Filing: 000095017023007710 The citation records this snapshot. The page link may show a newer release later.	−USD 61.03 million Exact value Exact value: -61026000 USD 2021-01-01 – 2021-12-31: -61026000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · RAPT Therapeutics, Inc. · 2021-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Operating Cash Flow: -61026000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -61026000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017023007710/rapt-20221231.htm#1904810 Filing: 000095017023007710 The citation records this snapshot. The page link may show a newer release later.	USD 755,000 Exact value Exact value: 755000 USD 2021-01-01 – 2021-12-31: 755000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · RAPT Therapeutics, Inc. · 2021-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Capital Expenditure: 755000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 755000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017023007710/rapt-20221231.htm#1926689 Filing: 000095017023007710 The citation records this snapshot. The page link may show a newer release later.	−USD 61.78 million Calculation and evidence -61026000 − 755000 USD Exact free cash flow: -61781000 USD 2021-01-01 – 2021-12-31: -61026000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 755000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · RAPT Therapeutics, Inc. · 2021-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Free cash flow: -61781000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -61026000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017023007710/rapt-20221231.htm#1904810 Filing: 000095017023007710 Input fundies:CapitalExpenditure: 755000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017023007710/rapt-20221231.htm#1926689 Filing: 000095017023007710 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 83.84 million Exact value Exact value: -83838000 USD 2022-01-01 – 2022-12-31: -83838000 USD Inspect Net Income Open source Share or cite Citation for Net Income · RAPT Therapeutics, Inc. · 2022-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Net Income: -83838000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -83838000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017024027594/rapt-20231231.htm#2166146 Filing: 000095017024027594 The citation records this snapshot. The page link may show a newer release later.	−USD 70.77 million Exact value Exact value: -70771000 USD 2022-01-01 – 2022-12-31: -70771000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · RAPT Therapeutics, Inc. · 2022-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Operating Cash Flow: -70771000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -70771000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017024027594/rapt-20231231.htm#1474963 Filing: 000095017024027594 The citation records this snapshot. The page link may show a newer release later.	USD 845,000 Exact value Exact value: 845000 USD 2022-01-01 – 2022-12-31: 845000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · RAPT Therapeutics, Inc. · 2022-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Capital Expenditure: 845000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 845000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017024027594/rapt-20231231.htm#1485790 Filing: 000095017024027594 The citation records this snapshot. The page link may show a newer release later.	−USD 71.62 million Calculation and evidence -70771000 − 845000 USD Exact free cash flow: -71616000 USD 2022-01-01 – 2022-12-31: -70771000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 845000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · RAPT Therapeutics, Inc. · 2022-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Free cash flow: -71616000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -70771000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017024027594/rapt-20231231.htm#1474963 Filing: 000095017024027594 Input fundies:CapitalExpenditure: 845000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017024027594/rapt-20231231.htm#1485790 Filing: 000095017024027594 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 116.8 million Exact value Exact value: -116798000 USD 2023-01-01 – 2023-12-31: -116798000 USD Inspect Net Income Open source Share or cite Citation for Net Income · RAPT Therapeutics, Inc. · 2023-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Net Income: -116798000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -116798000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017025034185/rapt-20241231.htm#2336259 Filing: 000095017025034185 The citation records this snapshot. The page link may show a newer release later.	−USD 97.05 million Exact value Exact value: -97048000 USD 2023-01-01 – 2023-12-31: -97048000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · RAPT Therapeutics, Inc. · 2023-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Operating Cash Flow: -97048000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -97048000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017025034185/rapt-20241231.htm#1523083 Filing: 000095017025034185 The citation records this snapshot. The page link may show a newer release later.	USD 1.13 million Exact value Exact value: 1125000 USD 2023-01-01 – 2023-12-31: 1125000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · RAPT Therapeutics, Inc. · 2023-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Capital Expenditure: 1125000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1125000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017025034185/rapt-20241231.htm#1536568 Filing: 000095017025034185 The citation records this snapshot. The page link may show a newer release later.	−USD 98.17 million Calculation and evidence -97048000 − 1125000 USD Exact free cash flow: -98173000 USD 2023-01-01 – 2023-12-31: -97048000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 1125000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · RAPT Therapeutics, Inc. · 2023-12-31 RAPT Therapeutics, Inc. (edgar:1673772) Free cash flow: -98173000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: f2113abb6052e96113f9e8f055328dbb91fb9893b73c582950f9b346b109817e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1673772?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -97048000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017025034185/rapt-20241231.htm#1523083 Filing: 000095017025034185 Input fundies:CapitalExpenditure: 1125000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1673772/000095017025034185/rapt-20241231.htm#1536568 Filing: 000095017025034185 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

40 filings · 1,562 latest values · 1,562 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001673772, 1673772, RAPT, edgar:1673772

Also known as FLX Bio, Inc., RAPT THERAPEUTICS, INC., RAPT Therapeutics, Inc.

RAPT Therapeutics, Inc.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation